NEW YORK, May 15 – Beyond Genomics said Tuesday it has entered its first corporate partnership, penning a deal with Elan Pharmaceuticalsto apply its systems biology techniques for Alzheimer's research.

In exchange for Beyond Genomics’ two-year commitment to the program, during which the companies will seek to find biomarkers and drug targets for Alzheimer's disease, Elan made a $5 million equity investment in the company.

Beyond Genomics did not disclose any more financial details.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.